Effect of grapefruit juice intake on etoposide bioavailability

European Journal of Clinical Pharmacology

Volumn 58, Issue 7, 2002, Pages 491-494

  Reif, Stefanie ^b,d   Nicolson, Marianne C ^c,d   Bisset, Donald ^c,d   Reid, Muriel ^c,d   Kloft, Charlotte ^b,d   Jaehde, Ulrich ^b,d   McLeod, Howard L ^a,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Cytochrome P450; Etoposide; Grapefruit juice; Oral chemotherapy

Indexed keywords

ETOPOSIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG INFUSION; FLUID INTAKE; GRAPEFRUIT JUICE; HUMAN; LUNG SMALL CELL CANCER; MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET RADIATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; CARCINOMA, SMALL CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS PARADISI; CROSS-OVER STUDIES; ETOPOSIDE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 0036032328     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0495-9     Document Type: Article

References (23)

1. McLeod HL, Evans WE (1999) Oral cancer chemotherapy: The promise and the pitfalls. Clin Cancer Res 5:2669-2671
2. Fujiwara Y, Ohune T, Okusaki K, Niitani K, Sumiyoshi H, Takemoto Y, Yamaoka N, Yamakido M (1996) Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. Cancer Chemother Pharmacol 37:327-331
3. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374-377
4. Hande K, Messenger M, Wagner J, Krozely M, Kaul S (1999) Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 5:2742-2747
5. Joel SP, Clark PI, Heap L, Webster L, Robbins S, Craft H, Slevin ML (1995) Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 37:125-133
6. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57
7. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR (1994) O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358
8. Stremetzne S, Jaehde U, Kasper R, Beyer J, Siegert W, Schunack W (1997) Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy. Eur J Cancer 33:978-979
9. Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490
10. Bailey DG, Malcolm J, Arnold O, Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110
11. Reif S, Kingreen D, Kloft C, Grimm J, Siegert W, Schunack W, Jaehde U (2001) Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. Cancer Chemother Pharmacol 48:134-140
12. Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior J (1985) Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69:269-273
13. Moukarzel AA, Sabri MT (1996) Gastric physiology and function: Effects of fruit juices. J Am Coll Nutr 15:18S-25S
14. Kane GC, Lipsky JJ (2000) Drug-grapefruit juice interactions. Mayo Clin Proc 75:933-942
15. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW (1998) Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 42:927-929
16. Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S (1999) Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol 55:393-398
17. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, Wrighton SA (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166
18. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res 59:3944-3948
19. Leu BL, Huang JD (1995) Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35:432-436
20. Perdaems N, Caunes N, Canal P, Chatelut E (1999) Possible excretion of etoposide via the intestinal mucosa. Cancer Chemother Pharmacol 43:520-521
21. Kobayashi K, Ratain MJ, Fleming GF, Vogelzang NJ, Cooper N, Sun BL (1996) A phase I study of CYP3A4 modulation of oral (po) etoposide with ketoconazole (KCZ) in patients (pts) with advanced cancer (CA). Proc Am J Clin Oncol 15:471
22. Takanaga H, Ohnishi A, Matsuo H, Sawada Y (1998) Inhibition of vinblastine effux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 21:1062-1066
23. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ (1999) Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 16:478-485